Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review. Issue 10 (3rd September 2019)

• Record Type: Journal Article
• Authors: Rich, Jessica D.; Clark, Stephen M.; Fedoriw, Yuri; Jewells, Valerie; Wood, William; Dittus, Christopher
• Is Part Of: Clinical case reports. Volume 7:Issue 10(2019)
• Page Start: 1957
• Page End: 1961
• Publication Date: 2019-09-03
• Subjects: BTK inhibitor -- central nervous system -- ibrutinib -- mantle cell lymphoma; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.2257
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Central nervous system (CNS)‐relapsed mantle cell lymphoma (MCL) is a rare, aggressive non‐Hodgkin lymphoma without a standard treatment. Ibrutinib has shown promising results for inducing remission in other non‐Hodgkin lymphomas and may be considered as successful treatment for CNS‐relapsed MCL in the future as well. Abstract : Central nervous system (CNS)‐relapsed mantle cell lymphoma (MCL) is a rare, aggressive non‐Hodgkin lymphoma without a standard treatment. Ibrutinib has shown promising results for inducing remission in other non‐Hodgkin lymphomas and may be considered as successful treatment for CNS‐relapsed MCL in the future as well.